What question did this study set out to answer?

To assess the safety and immunogenicity of an intranasally administered Sendai virus-based vaccine against human parainfluenza virus type 1 in healthy, seropositive children aged 3 to 6 years.

December 31, 2014Clinical and Vaccine ImmunologyOpen Access

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

View Full Paper

Ask AI

Bookmark

Authors

EAElisabeth E. AddersonSt. Jude Children's Research Hospital KBKristen BranumSt. Jude Children's Research Hospital RSRobert E. SealySt. Jude Children's Research Hospital

Discussion

Member takes

Implication

Dose-escalation trial demonstrates safety and increased antibody responses of an intranasal Sendai virus vaccine in children, suggesting potential protection against human parainfluenza.

Key Points

To assess the safety and immunogenicity of an intranasally administered Sendai virus-based vaccine against human parainfluenza virus type 1 in healthy, seropositive children aged 3 to 6 years.
Conducted a dose-escalation study administering a single intranasal dose of Sendai virus vaccine at 5 × 10^5, 5 × 10^6, or 5 × 10^7 50% egg infectious doses.
Enrolled healthy 3- to 6-year-old children with preexisting seropositivity to human parainfluenza virus type 1.
Monitored airway viral replication and evaluated antibody binding and neutralizing responses over a 6-month follow-up period.
The vaccine was well tolerated across all dose cohorts, with no evidence of viral replication detected in the airways of any participant.
Most children mounted an increase in antibody binding and neutralizing responses to human parainfluenza virus type 1 within 4 weeks of vaccination.
Elevated antibody levels remained above baseline values for at least 6 months after vaccination in several participants despite preexisting cross-reactive immunity.

Cite This Study

Adderson et al. (2014) studied this question.

synapsesocial.com/papers/6a8506e2abaf849ca59df088 https://doi.org/10.1128/cvi.00618-14

View Full Paper

Ask AI

Bookmark

Implication

Dose-escalation trial demonstrates safety and increased antibody responses of an intranasal Sendai virus vaccine in children, suggesting potential protection against human parainfluenza.

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider